Cosmetic eye redness
Cosmetic demand for reduced conjunctival hyperaemia without ocular pathology. The FDA approved brimonidine 0.025% (Lumify) for this use in the US. AEMPS has not registered such a product in Spain.
3 drugs
Also known as: Whitening eye drops, Tired-eye redness, Cosmetic conjunctival hyperaemia
Drugs used for this condition
Marketing claims without evidence base
The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.
- DCarbomerNot recommended · Artificial tear in gel form, polyacrylic polymerThe gel is bought «for red eyes», with moisturizing confused for whitening. Carbomer does not constrict vessels and does not remove redness: it only lubricates the surface, and the AEMPS ficha técnica says outright that the product contains no pharmacologically active substance. If the eye reddens from dryness, the gel removes the cause and the redness settles by itself, but there will be no «white eyes» within a minute. Nor is that worth waiting for: the vasoconstrictor drops that do produce it lead to rebound redness with regular use. One more thing: the gel blurs vision for 5 to 10 minutes, so it is inconvenient before going out. If carbomer gel was sold as a remedy for eye redness, consider seeking a second opinion from an ophthalmologist.
- FBrimonidineNot recommended · Topical selective α2-adrenergic agonist for ophthalmic useBrimonidine 0.1–0.2% in Spain is registered by AEMPS only for IOP lowering in glaucoma. A separate FDA-approved product Lumify 0.025% addresses cosmetic eye redness in the US; AEMPS has NOT registered such a product in Spain. Using the glaucoma 0.2% formulation for tired eyes or hangover does not work as a cosmetic agent and is dangerous: rebound hyperaemia worse than baseline appears after withdrawal, allergic conjunctivitis develops in up to 25% of patients by month six, and infants under six years can develop CNS depression and bradycardia. If brimonidine was suggested as daily whitening drops, consider seeking a second opinion.
How to read tiers A–F
Evidence tiers belong to the drug-indication pair, not to the drug as a whole: the same substance can be A for one condition and F for another.
- AStrong evidence – first or second line in international guidelines
- BRecommended in selected cases
- CStudy data contradict each other
- DBenefit not proven, no documented harm
- FDocumented harm, or risk without benefit